Objective: Interstitial lung disease (ILD) is a common extramuscular manifestation of the anti-synthetase syndrome (ASS). Patients with ASS-ILD are at risk in developing a progressive fibrosing phenotype despite appropriate treatments. This study investigated the risk factors and the predictive value of multiple risk factors for progressive pulmonary fibrosis (PPF) in patients with ASS-ILD. Methods: Ninety patients with a diagnosis of ASS and evidence of ILD on high-resolution computed tomography (HRCT) were recruited. Among them, 72 participants completed follow-up for more than 12 months. These patients were further divided into a PPF-ASS group (n = 18) and a non-PPF-ASS group (n = 54). Logistic regression analysis was performed to investigate the risk factors for PPF. The predictive value of the combined risk factors for predicting PPF were analyzed by a ROC curve. Results: The PPF-ASS group had a higher rate of positive non-Jo-1 antibodies, a significantly higher neutrophil-to-lymphocyte ratio (NLR) and serum lactate dehydrogenase (LDH), and a significantly lower PaO2/FiO2 ratio and diffusing capacity for carbon monoxide (DLCO%pred) than the non-PPF-ASS group. In addition, elevated serum Krebs von den Lungen-6 (KL-6) level and reticular opacities were significantly more common, and corticosteroid monotherapy at onset was administered more frequently in the PPF-ASS group. The median duration of follow-up was 37.4 months, survival was poorer in the PPF-ASS group, and the overall survival was 88.9%. Multivariate regression analysis further revealed that positive non-Jo-1 antibodies, NLR, and KL-6 were independent risk factors for PPF. These combined indexes had good accuracy (area under the curve = 0.874) in predicting PPF in patients with ASS-ILD. Conclusion: Positive non-Jo-1 antibodies, NLR, and serum KL-6 are independent risk factors for PPF in patients with ASS-ILD. Monitoring these markers can potentially predict PPF in this group of patients. Key Points• Positive non-Jo-1 antibodies, NLR, and serum KL-6 are independent risk factors associated with PPF in patients with ASS-ILD.• Monitoring non-Jo-1 antibodies, NLR, and serum KL-6 can potentially predict PPF in patients with ASS-ILD.
Coexisting anti‐MDA5 and anti‐PL‐7 antibodies are extremely rare. Anti‐MDA5 is associated with rapidly progressive interstitial lung disease (RP‐ILD), while anti‐PL‐7 is often associated with chronic or subacute ILD and better outcomes than RP‐ILD. We report a 41‐year‐old woman diagnosed with dermatomyositis (DM)‐associated ILD positive for anti‐MDA5 and anti‐PL‐7.
Background and Objectives: Usual interstitial pneumonia (UIP) is associated with progressive fibrosing interstitial lung diseases (PF-ILD) and poor survival in patients with fibrosing interstitial lung disease (FILD). We aimed to investigate the predictors of PF-ILD and survival in patients with FILD-UIP. Materials and Methods: This retrospective study was conducted at a single, tertiary hospital in China. Patients underwent routine follow-up visits every 3 to 6 months according to standard operating procedures (SOPs). Patients with FILD-UIP were further stratified using the proposed PF-ILD criteria. Results: This retrospective study enrolled 150 patients with FILD-UIP between October 2020 and June 2025, with 117 patients completing follow-up for more than 12 months. FILD-UIP was categorized as idiopathic pulmonary fibrosis (IPF) (n = 67) and non-IPF-UIP (n = 50), which included connective tissue disease-associated UIP (n = 29), hypersensitivity pneumonitis-associated UIP (n = 7), and interstitial pneumonia with autoimmune features-associated UIP (n = 14). During the follow-up period, 32 (47.8%) patients with IPF and 19 (38.0%) non-IPF-UIP experienced PF-ILD. Pulmonary hypertension (PH) and predicted percentage of forced vital capacity (FVC%pred) were dependent risk factors for PF-ILD in patients with FILD-UIP, non-IPF-UIP, and IPF. King’s Brief Interstitial Lung Disease (KBILD) is a dependent risk factor for PF-ILD in patients with FILD-UIP and IPF. PF-ILD is similarly associated with poor survival in patients with FILD-UIP, non-IPF-UIP, and IPF. Conclusions: Baseline disease severity is closely associated with the incidence of PF-ILD, with all forms of FILD-UIP at risk of PF-ILD and showing similar outcomes to IPF-UIP/PF-ILD.
Objectives: The study aimed to evaluate the efficacy of telemonitoring symptoms, oxygen saturation (SpO2) and heart rate (HR) at rest and after submaximal exercise using a telemonitoring application for early detection of acute exacerbations (AEs) of fibrosing interstitial lung diseases (F-ILDs). Methods: The data collected included symptoms, SpO2, and HR at rest and after submaximal exercise, which were obtained through the use of an online telemonitoring application called Respiratory Disease Steward. The symptoms assessed included the intensity and frequency of cough, as measured by the Cough Assessment Test scale score, and breathlessness grade, as measured by the Modified Medical Research Council scale score. Physiological parameters, such as SpO2 and HR, were also measured at rest and after a 1-minute sit-to-stand test (1STST). Results: The data collected from 85 patients with stable F-ILDs included changes in symptoms, SpO2, and HR at rest and after 1STST over a minimum of six months. The telemonitoring application was found to have an average recording duration of 255.4±78.1 days, with 21 patients experiencing an AE. The increase in COAT≥4 and mMRC≥1, the decrease in SpO2 at rest≥5% and SpO2 after 1STST ≥4% had the highest value in predicting the occurrence of AEs in patients with F-ILDs 2 weeks in advance (AUC=0.854). Conclusions: An effective approach in telemonitoring applications would be the recording of cough and breathlessness, as well as SpO2 at rest and after 1STST. The use of a composite COAT and mMRC, along with a significant decrease in SpO2 at rest and after 1STST, could successfully aid in the early detection of AE in patients with F-ILDs.